Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

NCT04582669 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped This study was administratively closed.

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: Intralesional Triamcinolone 10 mg/mL
DRUG: Intralesional Triamcinolone 20 mg/mL
DRUG: Intralesional Triamcinolone 40 mg/mL
DRUG: Placebo

Sponsor

Montefiore Medical Center